Biosimilar Pathway Quickly Becoming Crowded In U.S.
This article was originally published in The Pink Sheet Daily
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
You may also be interested in...
With two biosimilars set to move into Phase III this year, Oncobiologics hopes partnership with hospital services firm Premier will generate 'best practices around the optimal use of these cost-effective treatments.'
While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.
Growing number of products participating in BsUFA program, coupled with budgetary challenges, have made FDA attainment of some early goals under the Biosimilar User Fee Act difficult.